Browse studies

Find your next paid study

26,715 recruiting studies available now

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

Background: Focal segmental glomerulosclerosis (FSGS) is a disease that causes scarring in parts of the kidneys that filter waste. This can lead to protein lo…

Focal Segmental Glomerulosclerosis

Estimated

~$10 – $5,625

National Human Genome Research Institute (NHGRI)NCT06664814

Phase 2

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to sever…

Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07415044

Phase 2

The Gut Microbiome in Lean and Overweight Youth With Type 1 Diabetes and Novel Mechanism of Action of Metformin

Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is re…

Type 1 DiabetesObesity

Estimated

~$10 – $7,500

Heba M. IsmailNCT05414409

Phase 1

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.

This is a Phase 1, open-label, dose-escalation study of CBX-663 in participants with R/R AML, MDS or CMML (Cohort A), advanced solid tumors (Cohort B), or recu…

Advanced Solid TumorsRecurrent or Progressive GlioblastomaRelapse or Refractory Myeloid Malignancies

Estimated

~$10 – $8,750

Crossbow Therapeutics, Inc.NCT07779798

Phase 1

A Phase I Dose-escalation Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

Background: Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal glands. ACC often returns after tumors are removed with surgery. Less than 35% of p…

Adrenocortical Carcinoma (ACC)Recurrent Adrenocortical Carcinoma (ACC)Recurrent Abdominal Adrenocortical Carcinoma (ACC)+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06487481

Phase 2

A Phase 2, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Treatment Following Induction With Efgartigimod Administration in Adults With Myasthenia Gravis

The primary purpose of this study is to evaluate the efficacy of ublituximab in adult participants with MG responding to treatment with efgartigimod.

Myasthenia Gravis

Estimated

~$10 – $8,750

TG Therapeutics, Inc.NCT07673744

Phase 3

A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis

This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed …

Metabolic Dysfunction Associated Steatohepatitis

Estimated

~$10 – $7,500

Boehringer IngelheimNCT06632457

LORRAINE 2.5/3.5 mm Distal Humerus System - Post-Market Surveillance Study

Distal humerus fractures are fractures of the lower part of the upper arm bone near the elbow. These fractures often require surgery using plates and screws to…

Intra-Articular or Extra-Articular Distal Humerus FractureDistal Humerus Fracture

Estimated

~$10 – $1,050

Bonebridge AGNCT07774091

Understanding Stroke Outcomes: Stroke Resilience, Infarct Burden, and Long-Term Cognition

Background: Stroke is the fifth leading cause of death in the United States. It is also a leading cause of disability. More than 70% of people who survive str…

StrokeBrain DiseaseVascular Diseases+1 more

Estimated

~$10 – $675

National Institute of Neurological Disorders and Stroke (NINDS)NCT06615973

Phase 3

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with over…

OverweightObesity

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07282600

Phase 1

A Phase 1, Open-label, Multi-part Study to Evaluate Pharmacokinetics, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 Following Intravenous and Subcutaneous Administrations in Healthy Adults and Multiple Doses of BMS-986446 in Participants With Early Alzheimer's Disease.

The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in he…

Alzheimer's DiseaseHealthy Participants

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT07780383

Phase 3

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiat…

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05675410